DE69116144D1 - Bindung substratspezifischer affinitätssubstanzen an liposomen - Google Patents

Bindung substratspezifischer affinitätssubstanzen an liposomen

Info

Publication number
DE69116144D1
DE69116144D1 DE69116144T DE69116144T DE69116144D1 DE 69116144 D1 DE69116144 D1 DE 69116144D1 DE 69116144 T DE69116144 T DE 69116144T DE 69116144 T DE69116144 T DE 69116144T DE 69116144 D1 DE69116144 D1 DE 69116144D1
Authority
DE
Germany
Prior art keywords
liposomes
recognizing substances
crosslinking reagents
methodologies
substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69116144T
Other languages
English (en)
Other versions
DE69116144T2 (de
Inventor
Rimona Margalit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc filed Critical Baxter International Inc
Publication of DE69116144D1 publication Critical patent/DE69116144D1/de
Application granted granted Critical
Publication of DE69116144T2 publication Critical patent/DE69116144T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
DE69116144T 1991-02-14 1991-10-30 Bindung substratspezifischer affinitätssubstanzen an liposomen Expired - Fee Related DE69116144T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65587891A 1991-02-14 1991-02-14
PCT/US1991/008113 WO1992014447A1 (en) 1991-02-14 1991-10-30 Binding of recognizing substances to liposomes

Publications (2)

Publication Number Publication Date
DE69116144D1 true DE69116144D1 (de) 1996-02-15
DE69116144T2 DE69116144T2 (de) 1996-05-09

Family

ID=24630761

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69116144T Expired - Fee Related DE69116144T2 (de) 1991-02-14 1991-10-30 Bindung substratspezifischer affinitätssubstanzen an liposomen

Country Status (10)

Country Link
US (1) US5401511A (de)
EP (1) EP0525132B1 (de)
JP (1) JP3407072B2 (de)
AT (1) ATE132367T1 (de)
AU (1) AU651414B2 (de)
CA (1) CA2079444C (de)
DE (1) DE69116144T2 (de)
DK (1) DK0525132T3 (de)
ES (1) ES2084335T3 (de)
WO (1) WO1992014447A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5603872A (en) * 1991-02-14 1997-02-18 Baxter International Inc. Method of binding recognizing substances to liposomes
GB9208339D0 (en) * 1992-04-15 1992-06-03 Unilever Plc Treatment composition
US5759566A (en) * 1992-07-28 1998-06-02 Poli Industria Chimica Spa Microemulsion pharmaceutical compositions for the delivery of pharmaceutically active agents
US5654000A (en) * 1992-07-28 1997-08-05 Poli Industria Chimica S.P.A. Pharmaceutical compositions for transmucosal delivery of peptides
CA2140053C (en) * 1994-02-09 2000-04-04 Joel S. Rosenblatt Collagen-based injectable drug delivery system and its use
US5658588A (en) * 1995-03-31 1997-08-19 University Of Cincinnati Fibrinogen-coated liposomes
US6096863A (en) * 1996-08-23 2000-08-01 Regents Of The University Of Minnesota Self-assembling amphiphiles for construction of peptide secondary structures
EP0963196B1 (de) * 1996-09-27 2005-01-19 Jagotec Ag Arzneistoffverabreichungssystem mit hyaluronsäure
DE19852928C1 (de) * 1998-11-17 2000-08-03 Steffen Panzner Strukturen in Form von Hohlkugeln
EP1754488A1 (de) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten
US7893226B2 (en) * 2004-09-29 2011-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Use of lipid conjugates in the treatment of diseases
US8916539B2 (en) * 2000-01-10 2014-12-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
US8304395B2 (en) * 2000-01-10 2012-11-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Lipid conjugates in the treatment of disease
US8076312B2 (en) 2000-01-10 2011-12-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Use of lipid conjugates in the treatment of disease
US7608598B2 (en) * 2000-01-10 2009-10-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of conjunctivitis
US7393938B2 (en) * 2000-01-10 2008-07-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7772196B2 (en) 2000-01-10 2010-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US8501701B2 (en) * 2000-01-10 2013-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
US20090325876A1 (en) * 2004-09-29 2009-12-31 Saul Yedgar Use of lipid conjugates in the treatment of diseases associated with vasculature
US20060189569A1 (en) * 2000-01-10 2006-08-24 Saul Yedgar Use of lipid conjugates in the treatment of infection
US9040078B2 (en) * 2000-01-10 2015-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases of the nervous system
US7811999B2 (en) 2000-01-10 2010-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Use of lipid conjugates in the treatment of diseases
US10293056B1 (en) 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
WO2002020724A2 (en) 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Adenoviral targeting and manipulation of immune system response using targeting peptides
US8883761B2 (en) * 2001-01-10 2014-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases associated with vasculature
AU2002312543A1 (en) * 2001-08-01 2003-02-17 University Of Utah, Technology Transfer Office Isoform-selective inhibitors and activators of pde3 cyclic
US7544374B2 (en) * 2001-08-14 2009-06-09 Tel Aviv University Future Technology Development L.P. Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy
US6972173B2 (en) * 2002-03-14 2005-12-06 Intel Corporation Methods to increase nucleotide signals by raman scattering
US7238477B2 (en) * 2001-09-24 2007-07-03 Intel Corporation Methods to increase nucleotide signals by Raman scattering
FI115343B (fi) * 2001-10-22 2005-04-15 Filtronic Lk Oy Sisäinen monikaista-antenni
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
US7381426B2 (en) * 2002-01-24 2008-06-03 Southwest Research Institute Targeted delivery of bioactive factors to the systemic skeleton
US8728510B1 (en) 2002-03-15 2014-05-20 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing a bioadhesive material
US7476501B2 (en) * 2002-03-26 2009-01-13 Intel Corporation Methods and device for DNA sequencing using surface enhanced raman scattering (SERS)
US20040110208A1 (en) * 2002-03-26 2004-06-10 Selena Chan Methods and device for DNA sequencing using surface enhanced Raman scattering (SERS)
US7361821B2 (en) * 2002-09-20 2008-04-22 Intel Corporation Controlled alignment of nanobarcodes encoding specific information for scanning probe microscopy (SPM) reading
WO2004038037A2 (en) * 2002-09-20 2004-05-06 Intel Corporation Controlled alignment of nano-barcodes encoding specific information for scanning probe microscopy (spm) reading
US7270952B2 (en) * 2002-09-24 2007-09-18 Intel Corporation Detecting molecular binding by monitoring feedback controlled cantilever deflections
AU2003278903A1 (en) * 2002-09-24 2004-04-19 Intel Corporation Detecting molecular binding by monitoring feedback controlled cantilever deflections
MXPA05006193A (es) 2002-12-11 2005-12-05 Ferrosan As Materiales basados en gelatina como hisopos.
US6861251B2 (en) 2003-02-24 2005-03-01 Pritest, Inc. Translucent solid matrix assay device for microarray analysis
WO2005020965A2 (en) * 2003-08-21 2005-03-10 Southwest Research Institute Skeletally targeted nanoparticles
US20050064435A1 (en) * 2003-09-24 2005-03-24 Xing Su Programmable molecular barcodes
US20050147976A1 (en) * 2003-12-29 2005-07-07 Xing Su Methods for determining nucleotide sequence information
US9062392B2 (en) 2003-12-30 2015-06-23 Intel Corporation Methods for isolating a peptide methods for identifying a peptide
US20050147980A1 (en) * 2003-12-30 2005-07-07 Intel Corporation Nucleic acid sequencing by Raman monitoring of uptake of nucleotides during molecular replication
US20050147979A1 (en) * 2003-12-30 2005-07-07 Intel Corporation Nucleic acid sequencing by Raman monitoring of uptake of nucleotides during molecular replication
US20050147964A1 (en) * 2003-12-30 2005-07-07 Intel Corporation Methods for identifying a peptide that binds a geometrical shape
JP2007519450A (ja) * 2004-01-30 2007-07-19 フェロサン アー／エス 止血用のスプレーおよび組成物
US20050221507A1 (en) * 2004-03-30 2005-10-06 Intel Corporation Method to detect molecular binding by surface-enhanced Raman spectroscopy
FR2870741B1 (fr) * 2004-05-25 2008-03-14 Coletica Sa Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant.
CA2571981C (en) * 2004-07-09 2014-12-30 Ferrosan A/S Haemostatic composition comprising hyaluronic acid
US8808664B2 (en) * 2004-07-13 2014-08-19 Ramot At Tel-Aviv University Ltd. Lipidated glycoprotein particles and methods of use
US7709247B2 (en) * 2004-08-04 2010-05-04 Intel Corporation Methods and systems for detecting biomolecular binding using terahertz radiation
US20060210549A1 (en) * 2004-09-10 2006-09-21 Srivastava Devendra K Controlled release liposomes and methods of use
CA2585754C (en) 2004-11-02 2014-12-23 Tel-Aviv University Future Technology Development L.P. Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles and their use for diagnostics and therapy
CN104546891A (zh) * 2005-08-03 2015-04-29 塞尔索斯治疗公司 脂质结合物在囊性纤维化病中的用途及其应用
WO2007041627A1 (en) * 2005-10-03 2007-04-12 Pinsky Mark A Compositions and methods for improved skin care
US8859524B2 (en) 2005-11-17 2014-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of chronic rhinosinusitis
US8906882B2 (en) 2005-11-17 2014-12-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of allergic rhinitis
EP3067046B1 (de) 2005-12-08 2020-03-25 Insmed Incorporated Antiinfektive zusammensetzungen auf lipidbasis zur behandlung von lungeninfekten
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
US20080183282A1 (en) * 2006-03-09 2008-07-31 Saul Yedgar Use of lipid conjugates for the coating of stents and catheters
WO2007127272A2 (en) * 2006-04-24 2007-11-08 The Cbr Institute For Biomedical Research Method of producing immunoliposomes and compositions thereof
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8119156B2 (en) * 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8071127B2 (en) * 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
AU2007320737B2 (en) * 2006-11-14 2014-04-03 Celsus Therapeutics Plc Contact lens compositions
CA2705785A1 (en) * 2006-11-14 2008-05-22 Saul Yedgar Use of lipid conjugates in the treatment of diseases or disorders of the eye
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
RU2488592C2 (ru) 2007-08-08 2013-07-27 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Пептиды направленного действия на vegfr-1/nrp-1
US8632803B2 (en) 2008-02-27 2014-01-21 Ramot At Tel-Aviv University Ltd. System for delivery of protein in insoluble fibrillar or aggregate form
CN102014973A (zh) 2008-02-29 2011-04-13 弗罗桑医疗设备公司 用于促进止血和/或伤口愈合的装置
WO2010107658A2 (en) 2009-03-16 2010-09-23 Vallera Daniel A Methods and compositions for bi-specific targeting of cd19/cd22
AU2010247814B2 (en) 2009-05-11 2015-08-13 Celsus Therapeutics Plc Lipid-polymer conjugates, their preparation and uses thereof
GB0913442D0 (en) 2009-07-31 2009-09-16 Univ Ramot Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
US20120269721A1 (en) * 2009-10-12 2012-10-25 The Regents Of The University Of California Targeted nanoclusters and methods of their use
US10179106B2 (en) * 2011-05-12 2019-01-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Liposomes comprising polymer-conjugated lipids and related uses
EP2822474B1 (de) 2012-03-06 2018-05-02 Ferrosan Medical Devices A/S Druckbehälter mit einer blutstillenden paste
WO2013156989A1 (en) 2012-04-18 2013-10-24 Ramot At Tel-Aviv University Ltd. Lipidated glycosaminoglycan particles for the delivery of nucleic acids
BR112014030962A2 (pt) 2012-06-12 2017-06-27 Ferrosan Medical Devices As métodos para preparação e para reconstituição de uma composição seca adequada para uso em hemostase e cicatrização de feridas, e, kit hemostático
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
US9724078B2 (en) 2013-06-21 2017-08-08 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
MX2016005232A (es) 2013-10-22 2017-01-19 Aradigm Corp Formulaciones liposomicas para inhalacion, modificadas con agente tensoactivo, que proveen un perfil de liberacion tanto inmediata como sostenida.
EP3470094B1 (de) 2013-12-11 2020-07-22 Ferrosan Medical Devices A/S Trockenzusammensetzung mit extrusionsverstärker
DK3466432T3 (da) 2014-05-15 2020-09-28 Insmed Inc Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
EP3160448A4 (de) 2014-06-26 2018-11-14 Ramot at Tel-Aviv University Ltd. Liposomale formulierungen zur freisetzung von nukleinsäuren
WO2016058612A1 (en) 2014-10-13 2016-04-21 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
WO2016102446A1 (en) 2014-12-24 2016-06-30 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
WO2017005590A1 (en) 2015-07-03 2017-01-12 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
JP7197106B2 (ja) * 2018-04-27 2022-12-27 国立大学法人北海道大学 脂質ナノ粒子
EP4321182A2 (de) 2018-05-09 2024-02-14 Ferrosan Medical Devices A/S Verfahren zur herstellung einer hämostatischen zusammensetzung

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
JPS59210013A (ja) * 1983-05-04 1984-11-28 Ajinomoto Co Inc 活性物質含有リポソ−ム
US4708861A (en) * 1984-02-15 1987-11-24 The Liposome Company, Inc. Liposome-gel compositions
US4761288A (en) * 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
WO1986004232A1 (en) * 1985-01-18 1986-07-31 Cooper-Lipotech, Inc. Liposome composition and method
FR2597345B1 (fr) * 1986-04-22 1990-08-03 Oreal Composition cosmetique ou pharmaceutique a base d'une dispersion aqueuse de spherules lipidiques.
JPH02500360A (ja) * 1986-07-28 1990-02-08 リポソーム　テクノロジー，インコーポレイテッド 粘膜組織上での高い保持力を有するリポソーム
US4839175A (en) * 1986-07-28 1989-06-13 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
US5000960A (en) * 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
WO1989011270A1 (en) * 1988-05-16 1989-11-30 Sandoz Ag Liposomes coupled to hormones
ATE78156T1 (de) * 1988-12-02 1992-08-15 Coletica Stabilisierung von hydratierten lamellaren phasen.
FR2645741B1 (fr) * 1989-03-20 1995-06-23 Dior Christian Parfums Procede pour fixer un produit sur la membrane d'un keratinocyte au moyen d'une liaison ligand-recepteur, procede de preparation d'un tel produit, produit obtenu, composition cosmetique ou pharmaceutique le contenant et son procede de preparation
AU652778B2 (en) * 1990-10-15 1994-09-08 Quest International B.V. Treatment composition
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system

Also Published As

Publication number Publication date
CA2079444C (en) 2004-02-03
CA2079444A1 (en) 1992-08-15
ES2084335T3 (es) 1996-05-01
DK0525132T3 (da) 1996-02-05
ATE132367T1 (de) 1996-01-15
AU9037091A (en) 1992-09-15
AU651414B2 (en) 1994-07-21
JP3407072B2 (ja) 2003-05-19
JPH05505827A (ja) 1993-08-26
EP0525132B1 (de) 1996-01-03
DE69116144T2 (de) 1996-05-09
WO1992014447A1 (en) 1992-09-03
EP0525132A1 (de) 1993-02-03
US5401511A (en) 1995-03-28

Similar Documents

Publication Publication Date Title
DE69116144D1 (de) Bindung substratspezifischer affinitätssubstanzen an liposomen
ES2138584T3 (es) Sistema de suministro de farmacos que implica la reaccion entre una proteina o un polipeptido y un polimero biodegradable hidrofobo.
ES2149867T3 (es) Derivados de polisacaridos y soportes para farmacos.
FI945912A (fi) Proteinoidikantajat ja menetelmät niiden valmistamiseksi sekä niiden käyttö
HK1041011A1 (en) Cross-linked hyaluronic acids and medical uses thereof
CA2135062A1 (en) Pharmaceutical and Other Dosage Forms
AU6950596A (en) Laser assisted drug delivery
DK0750494T3 (da) Hydrofobe lægemiddelafgivelsessystemer
FR2730637B1 (fr) Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
NO2004004I2 (no) Bortezomib eller en farmasøytisk akseptabel ester derav, eventuelt i form av et farmasøytisk akseptabelt salt derav
AU5740996A (en) Method for drug delivery to the pulmonary system
DE69627769D1 (de) Funktionelle Faserprodukte
FI941777A0 (fi) Vesipitoinen farmaseuttinen suspensio ja menetelmä sen valmistamiseksi
MX9709028A (es) Suministro de aciclovir oral.
ATE203072T1 (de) Zusammensetzung und verfahren zur papierleimung
IT7823679A0 (it) Processo enzimatico-microbiologico per la produzione di amminoacidi otticamente attivi a partire da idantoine e/o carbamil-derivati racemi.
DE69840150D1 (de) Verfahren, basierend auf affinitätskreuzbindung, der interaktion von biologisch aktiven peptiden an antikörper
AU1431188A (en) Dihydropyridine - pyridinium salt-type redox amino acids and peptides containing them
SE9501285L (sv) Förfarande för framställning av biologiskt aktiva proteiner
ITTO930519A0 (it) Procedimento di sintesi di acidi cloroacetici.
PL319157A1 (en) Pka bonding novel proteins an dtheir application
ATE211383T1 (de) Topische aciclovir-zubereitung
TR199600772A2 (tr) 2-(4-Pirazoliloksi-Pirimidin-5-il) asetik asit türevleri.
AU629008B2 (en) Compounds from biopolymrs and effector substances which are linked via optically active amino acid derivatives, processes for the preparation thereof and the use thereof
AU1166997A (en) Trans apovincaminic acid ester derivatives as drugs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee